Minoxidil vs RU-58841
FDA Approved vs Limited Research
compatible RU-58841 is a topical non-steroidal androgen receptor antagonist that blocks DHT at the follicular level. It operates through a different mechanism than minoxidil and can be used alongside it. RU-58841 lacks FDA approval and has limited clinical safety data, so users should exercise caution.
Molecular Data
Minoxidil RU-58841
Weight 209.25 Da 369.34 Da
Half-life ~4 hours (oral); topical effects persist significantly longer due to local tissue retention ~1 hour topically (very short systemic half-life)
Type Synthetic pyrimidine derivative (6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine) Non-steroidal anti-androgen
Key Benefits
Minoxidil
01 FDA-approved for androgenetic alopecia with decades of clinical evidence
02 Stimulates new hair growth and increases hair follicle size independent of androgen pathways
03 Available over the counter as a topical treatment without a prescription
04 Effective in both men and women for pattern hair loss
05 Low-dose oral formulation offers a convenient once-daily alternative to twice-daily topical application
06 Synergistic with finasteride and dutasteride for a multi-mechanism approach to hair loss
07 Extends the anagen (growth) phase and shortens the telogen (resting) phase of the hair cycle
RU-58841
01 Blocks DHT directly at the androgen receptor in hair follicles without reducing systemic DHT levels
02 Extremely short systemic half-life limits risk of systemic anti-androgenic side effects
03 Different mechanism of action from finasteride/dutasteride, allowing combination therapy
04 Animal studies demonstrated significant hair regrowth in androgen-dependent alopecia models
05 Topical application targets the site of action directly
06 Does not interfere with systemic testosterone or DHT levels
Side Effects
Minoxidil
Scalp irritation, dryness, or flaking (topical, especially solution formulations containing propylene glycol)
Initial shedding phase during the first 1-3 months of treatment
Hypertrichosis (unwanted facial and body hair growth, more common with oral administration)
Fluid retention and mild peripheral edema (oral)
Mild dizziness or lightheadedness upon standing (oral, due to vasodilation)
RU-58841
Scalp irritation, dryness, or itching at the application site (often related to the vehicle/solvent rather than RU-58841 itself)
Contact dermatitis in sensitive individuals
Scalp flaking or peeling
Contraindications
Known hypersensitivity to minoxidil or any component of the formulation
Pheochromocytoma (minoxidil may stimulate catecholamine release)
Significant cardiovascular disease, including history of pericardial effusion or congestive heart failure
Concurrent use of potent antihypertensive medications without physician supervision (risk of additive hypotension)
Pregnancy and breastfeeding (Category C; oral minoxidil has shown evidence of fetal harm in animal studies)
Women who are pregnant or may become pregnant (anti-androgens can cause feminization of a male fetus)
Women who are breastfeeding
Known hypersensitivity to RU-58841 or related non-steroidal anti-androgens
Active scalp infections, open wounds, or severely compromised skin barrier on the scalp
Individuals taking systemic anti-androgens (risk of additive anti-androgenic effects)
Research Evidence
Minoxidil RU-58841
Status FDA Approved Limited Research
References 5 studies 4 studies
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.